On May 26, 2026, Ali-Jackson Kamil, a director at Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), sold 2,500 shares of the company’s stock for $72,925, at a price of $29.17 per share. Following this transaction, Kamil retains 12,625 shares. The sale was part of a pre-arranged 10b5-1 trading plan initiated on November 7, 2025. Despite the sale, Rigel's stock has appreciated to $30.05, reflecting a 54% return over the past year. In recent financial disclosures, Rigel reported a 26% increase in net product sales for the first quarter of 2026, totaling $54.9 million. This growth was largely driven by a 31% rise in sales of TAVALISSE, the company’s flagship product. Additionally, Rigel announced a global licensing agreement for Veppanu, a breast cancer treatment developed by Arvinas Inc. and Pfizer Inc., granting it exclusive rights for development and commercialization. This strategic move is expected to bolster Rigel's position in the oncology market and diversify its revenue streams.